Boston Scientific Reports Strong Q2 2025 Results with Cardiovascular Revenue Up 26.8%

On July 23, Boston Scientific announced its second-quarter financial report.Exceeding Market Expectations, and simultaneously raised the full-year adjusted earnings per share (EPS) and revenue growth guidance. The stock price rose more than 3% during the trading session, reaching $106.47.

According to the financial report, the company achievedNet profit of $7.97 billion, a significant increase from $324 million in the same period last year. Revenue for the same period was $5.06 billion, a year-on-year increase of 22.8%, also higher than the Wall Street expectation of $4.89 billion.

Cardiovascular Business Leads the Growth, Multiple Product Lines Show Outstanding Performance

From the perspective of business segments,Cardiovascular product revenue increased by 26.8% year-over-year, serving as the primary growth driver. The MedSurg segment grew by 15.7%, with strong performances in细分业务: Cardiology (29.3% growth), Urology (28.9% growth), and Peripheral Interventions (18.3% growth).

In addition, the company completed the acquisitions of SoniVie, Bolt Medical, and Intera Oncology this quarter, further expanding its product and technology portfolio.

Mike Mahoney, Chairman and Chief Executive Officer of Boston Scientific"This is another outstanding quarter — while achieving rapid revenue growth, we have improved profitability and continued to increase investments for the future. Thanks to the global team's excellent performance in both clinical and commercial fields, we have built long-term differentiated competitive advantages for the company."

Raise Full-Year Guidance, Positive on New Growth Points like PFA Far-Field Ablation

The company raised its full-year 2025 adjusted EPS guidance to $2.95-$2.99 (from $2.87-$2.94 previously) and increased its revenue growth forecast from 15%-17% to 18%-19%.

During the earnings call, Chief Medical Officer Dr. Ken Stein stated that the company is expected to benefit from the new payment policy proposed by the U.S. CMS (Centers for Medicare & Medicaid Services) – a proposal that would allow ambulatory surgery centers to provide Medicare reimbursement for cardiac ablation procedures, including Farapulse pulsed field ablation (PFA).

At the same time, the National Institute for Health and Care Excellence (NICE) in the UK also recommended PFA technology for atrial fibrillation treatment this month, adding another advantage for the company in the global market expansion.

Market Analysis: Farapulse and Watchman Form a "Golden Combination"

Despite previously voluntarily discontinuing its Accurate TAVR (Transcatheter Aortic Valve Replacement) product line due to stricter regulatory requirements in the U.S. and Europe, thereby exiting competition in this field after the Lotus project, multiple analytical firms continue to view Boston Scientific's mid- to long-term growth potential favorably.

Truist analyst Richard Newitter noted that the company's Farapulse PFA system for atrial fibrillation treatment and the Watchman device for left atrial appendage closure have become its growth engines.

This month, two products have received expanded indications approval from the U.S. FDA, further enhancing their market competitiveness.